When was Proxima founded?

Proxima was founded in 2019 and raised its 1st funding round 7 years after it was founded.

Where is Proxima located?

Proxima is headquartered in New York City, United States.

Who is the current CEO of Proxima?

Zachary Carpenter of Proxima. They have also founded 1 company.

How many employees does Proxima have?

As of Sep 30, 2026, the latest employee count at Proxima is 75.

Is Proxima a funded company?

Proxima is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jan 12, 2026.

When was the latest funding round of Proxima?

Proxima's latest funding was a $***** Seed round on Jan 12, 2026, with participation from 9 investors.

Where does Proxima rank among its competitors?

Proxima ranks 20th amongst 80 active competitors, of which 44 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Proxima, which secured $86.3M in Jan, 2026.

Who are the top competitors of Proxima?

Proxima's top competitors include Nimbus Therapeutics, Generate Biomedicines and Cradle. Among them, Proxima secured the most recent funding round in January, 2026.

Proxima - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of a platform for programmable protein interaction-based drug discovery. The company offers technologies to discover proximity modulators, including inducers, modulators, and blockers. It focuses on advancing artificial intelligence drug discovery through data generation.

Website: proximabio.com
Social
Email ID: *****@proximabio.com

Key Metrics

Founded Year

2019

Location

New York City, United States

Stage

Seed

Total Funding

$86.3M in 1 round

Latest Funding Round

Seed, Jan 12, 2026, $*****

Investors

DCVC & 8 more

Ranked

20^th among 80 active competitors

Employee Count

75 as on Sep 30, 2026

Similar Companies

Nimbus Therapeutics & 84 more

View Proxima's full profile

Proxima has raised a total funding of $86.3M over 1 round. Its latest funding round was a Seed round on Jan 12, 2026 for $*****. 9 investors participated in its latest round. Proxima has 9 institutional investors.

Here is the list of recent funding rounds of Proxima:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 12, 2026	1245387	Seed	5480783	7835735	9141394	7023955

Access funding benchmarks and valuations. Sign up today!

View details of Proxima's funding rounds and investors

The founders of Proxima is Zachary Carpenter. Zachary Carpenter is the CEO of Proxima.

Here are the details of Proxima's key team members:

Zachary Carpenter: Co-Founder & CEO of Proxima.

View details of Proxima's Founder profiles and Board Members

Proxima's employee count trend

Proxima has 75 employees as of Sep 26. Here is Proxima's employee count trend over the years:

Uncover Proxima's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Proxima include Nimbus Therapeutics, Generate Biomedicines and Cradle. Here is the list of Top 10 competitors of Proxima, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
2nd	Generate Biomedicines 2018, Somerville (United States), Public	Developer of a platform for generating novel protein-based therapeutic modalities	$693M	Pictet Group, NVentures & 14 others	66/100
3rd	Cradle 2021, Zurich (Switzerland), Series B	Provider of chemoproteomics solutions for protein design and development	$103M	Index Ventures, Kindred Capital & 7 others	64/100
4th	EvolutionaryScale 2023, New York City (United States), Seed	Provider of an AI models for protein design	$142M	Lux Capital, Amazon & 3 others	64/100
5th	Profluent Bio 2022, Berkeley (United States), Series B	Provider of an artificial intelligence-based protein design platform	$150M	Spark Capital, Insight Partners & 6 others	64/100
6th	Frontier Medicines 2018, San Francisco (United States), Series C	Developer of a bioinformatics platform for drug development and chemoproteomics	$236M	Deerfield, Woodline Partners & 11 others	62/100
7th	Eikon 2019, Millbrae (United States), Public	Protein tracking and measuring tool for drug discovery	$1.16B	The Column Group, T. Rowe Price & 22 others	62/100
8th	Seismic 2019, Watertown (United States), Series B	AI-assisted platform for drug discovery and development	$247M	Bessemer Venture Partners, Lightspeed Venture Partners ... & 12 others	62/100
9th	Vividion Therapeutics 2016, Oceanside (United States), Acquired	Pioneering chemoproteomics and covalent chemistry for precision therapeutics targeting undruggable disease drivers	$271M	Boxer Capital, Nextech Invest & 21 others	61/100
10th	Orbit Discovery 2015, Oxford (United Kingdom), Series A	Developer of a drug discovery platforms by peptide display engine	$15.7M	Oxford Science Enterprises, Innovate UK & 11 others	59/100
20th	Proxima 2019, New York City (United States), Seed	Developer of a platform for programmable protein interaction-based drug discovery	$86.3M	NVentures, Roivant Sciences & 7 others	48/100